Hepatocellular Carcinoma — Expanded Access Programs
Overview
Right2Hope maintains a directory of 74 expanded access programs, clinical trials, and compassionate use pathways listed for Hepatocellular Carcinoma. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with hepatocellular carcinoma programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 29 programs are currently active or recruiting, with the remaining 45 in other lifecycle stages. Sponsors actively running programs in this area include AstraZeneca, National Cancer Institute (NCI), Mayo Clinic, AbbVie, Anwaar Saeed, and others.
By recruiting status
Snapshot of where every Hepatocellular Carcinoma program currently sits in its lifecycle.
- Active / Recruiting29
- Inactive45
Top sponsors
Organisations running the most Hepatocellular Carcinoma programs in the directory.
- AstraZeneca7 programs
- National Cancer Institute (NCI)4 programs
- Mayo Clinic3 programs
- AbbVie2 programs
- Anwaar Saeed2 programs
- Bristol-Myers Squibb2 programs
- Exelixis2 programs
- Teclison Ltd.2 programs
- The Methodist Hospital Research Institute2 programs
- University of California, Irvine2 programs
Hepatocellular Carcinoma programs (74)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on Using [18F]FAPI-74 PET Imaging for Detecting Cancer — National Cancer Institute (NCI)
- Global Study on TACE with Durvalumab and Bevacizumab for Liver Cancer — AstraZeneca
- Study on Durvalumab or Tremelimumab Alone, or Combined with Tremelimumab or Bevacizumab for Advanced Liver Cancer — MedImmune LLC
- Study on Nivolumab and Ipilimumab for Advanced Liver Cancer — Bristol-Myers Squibb
- Study on Nivolumab for Liver Cancer Patients at High Risk of Cancer Returning After Surgery or Ablation — Bristol-Myers Squibb
- Study on Nofazinlimab (CS1003) for Advanced Liver Cancer — CStone Pharmaceuticals
- Study of Valemetostat Tosylate with Atezolizumab and Bevacizumab for Advanced Liver Cancer — University of Alabama at Birmingham
- Study on Casdozokitug with Toripalimab and Bevacizumab for Advanced Liver Cancer — Coherus Biosciences, Inc.
- Study on Durvalumab Alone or with Bevacizumab for Preventing Return of Liver Cancer After Treatment — AstraZeneca
- Study on Atezolizumab and Bevacizumab with Y90 Radioembolization for Liver Cancer Patients Awaiting Transplant — Icahn School of Medicine at Mount Sinai
- Study on Cabozantinib and Durvalumab, With or Without Tremelimumab, for Patients with Gastroesophageal and Other Gastrointestinal Cancers — Anwaar Saeed
- Study on Cabozantinib-S-Malate for Treating Young Patients with Sarcomas, Wilms Tumor, or Other Rare Tumors — National Cancer Institute (NCI)
- Study to Find the Best Dose of Tirapazamine with Embolization for Liver Cancer — Teclison Ltd.
- First Human Study of AZD9793 for Advanced or Metastatic Solid Tumors — AstraZeneca
- Study on Lenvatinib and TACE Combination Therapy Before Liver Transplant for Large Liver Cancer — The Methodist Hospital Research Institute
- Study on Patient Preference for Subcutaneous vs. Intravenous Immune Therapy — Diwakar Davar
- Phase II Study of Enfortumab Vedotin for Patients with Advanced Colorectal or Liver Cancer — H. Lee Moffitt Cancer Center and Research Institute
- Phase III Study of Rilvegostomig and Bevacizumab, With or Without Tremelimumab, for First-line Treatment of Liver Cancer — AstraZeneca
- Study on Simvastatin for Preventing Liver Cancer in Patients with Liver Cirrhosis — National Cancer Institute (NCI)
- Study on Sorafenib and Doxorubicin for Advanced Liver Cancer After Sorafenib Treatment — Memorial Sloan Kettering Cancer Center
- Study on DPX-Survivac with Low Dose Cyclophosphamide and Pembrolizumab for Advanced and Recurrent Solid Tumors — ImmunoVaccine Technologies, Inc. (IMV Inc.)
- Study on Cabozantinib and Atezolizumab vs. Sorafenib for Advanced Liver Cancer — Exelixis
- Study on Cabozantinib and Atezolizumab vs. Sorafenib for Advanced Liver Cancer in Patients Without Prior Treatment — Exelixis
- Study on New Immune System Drugs Alone and with Cancer Treatments for Advanced Liver and Bile Duct Cancer — AstraZeneca
- Study on Tremelimumab and Durvalumab for Advanced Liver Cancer with Child-Pugh-B Cirrhosis — The University of Texas Health Science Center at San Antonio
- Study on PF-08634404 for Advanced Liver Cancer (Hepatocellular Carcinoma) — Pfizer
- Home-Based Cancer Treatment Program for Patients in the Florida Panhandle and Nearby Areas — Mayo Clinic
- Study on Y-90 Treatment Response Using Transarterial Radioembolization for Liver Cancer — Thomas Jefferson University
- Study on Zanzalintinib (XL-092) with Durvalumab and Tremelimumab for Unresectable Liver Cancer (ZENOBIA) — Anwaar Saeed
- Study on 68Ga-PSMA-11 PET-directed Radioligand Therapy for Advanced Liver Cancer — Melissa Lumish
- Study on 68Ga-PSMA-Dual-Contrast PET/MRI or PET/CT for Early Detection of Liver Cancer — Mayo Clinic
- Study on OTX-2002 for Liver Cancer and Other Tumors Linked to the MYC Gene — Omega Therapeutics
- Study on AZD5851 for Advanced or Returning Liver Cancer with GPC3 Marker — AstraZeneca
- Study on Memantine for Patients with Cirrhosis and Liver Cancer — Inova Health Care Services
- Study on Atezolizumab, With or Without Bevacizumab, for Patients with Unremovable Liver Cancer and Certain Liver Conditions — Genentech, Inc.
- Study on Oral Alintegimod with Ipilimumab and Nivolumab for Cancer Treatment — 7 Hills Pharma, LLC
- Study of TTI-101 Alone and in Combination for Advanced Liver Cancer — Tvardi Therapeutics, Incorporated
- Study on the Effects and Safety of Livmoniplimab and Budigalimab for Liver Cancer — AbbVie
- Study on AI-Based Drug Dosing for Liver Cancer Treatment — University of Florida
- Study on IP-001 Treatment for Liver Cancer Patients After Surgery or Ablation — Robert C. Martin
- An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma — Virogin Biotech Canada Ltd
- Study on Anti-PD-1 Antibody with Metabolic Modulator for Treating Solid Tumors — Dan Zandberg
- Study on Atezolizumab and Bevacizumab with TACE for Patients with Intermediate Stage Liver Cancer — Yale University
- Study on Atezolizumab and Bevacizumab Before Liver Transplant for Liver Cancer Patients Outside Standard Criteria — The Methodist Hospital Research Institute
- Study on BI-1910 Alone and with Pembrolizumab for Treating Advanced Solid Tumors — BioInvent International AB
- Study on BOXR1030 T Cells for Treating Advanced GPC3-Positive Solid Tumors — Sotio Biotech Inc.
- Study on Cabozantinib Combined with Ipilimumab/Nivolumab and TACE for Liver Cancer — University of California, Irvine
- Study on Combining TATE and PD-1 Inhibitor for Liver Cancer — Teclison Ltd.
- Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab, and TACE for Liver and Biliary Tract Cancer — National Cancer Institute (NCI)
- Study Comparing In-Home and In-Clinic Administration of Nivolumab for Cancer Patients — Mayo Clinic
- Domvanalimab and Zimberelimab in Advanced Liver Cancers — University of Texas Southwestern Medical Center
- Study on Durvalumab, Tremelimumab, and Radiation Therapy for Liver and Biliary Tract Cancer — Massachusetts General Hospital
- Study on Durvalumab and Tremelimumab for Liver Cancer in Patients Awaiting Liver Transplant — Davendra Sohal
- Study on Combining Durvalumab, Tremelimumab, and Lenvatinib with TACE for Patients with Localized Liver Cancer — AstraZeneca
- Study on the Duration of PD-1/PD-L1 Inhibitor Treatment in Advanced Solid Tumors — Jason J. Luke, MD
- Evaluating Novel Therapies in ctDNA Positive GI Cancers — Georgetown University
- Expanded Access to Ulixertinib (BVD-523) in Patients with Advanced MAPK Pathway-Altered Malignancies — xCures
- Study on GT90001 and Nivolumab for Patients with Advanced Liver Cancer — Suzhou Kintor Pharmaceutical Inc,
- Study on Intravenous T3011 Alone and with Other Treatments for Advanced Solid Tumors — ImmVira Pharma Co. Ltd
- Comparing Localized and Systemic Treatments for Patients with Intermediate-Stage Liver Cancer (HCC) — University of Texas Southwestern Medical Center
- Study on Maintenance Treatment with Zanzalintinib and Durvalumab for Advanced Liver Cancer — Amit Mahipal
- Study on Namodenoson for Treating Advanced Liver Cancer in Patients with Moderate Liver Damage — Can-Fite BioPharma
- Study on Cemiplimab Before Surgery for Treating Resectable Lung, Liver, and Head and Neck Cancers in Adults — Regeneron Pharmaceuticals
- Study on Combination Immunotherapies for Patients Previously Treated with Immune Checkpoint Inhibitors — ImmunityBio, Inc.
- Study on Regorafenib and Yttrium-90 Radioembolization for Liver Cancer That Cannot Be Removed by Surgery — University of Miami
- Study on the Safety and Effectiveness of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Children with Solid Tumors — St. Jude Children's Research Hospital
- Study on the Safety and Effectiveness of Pembrolizumab Compared to Placebo for Liver Cancer Patients After Surgery or Local Treatment — Merck Sharp & Dohme LLC
- Study on RP2 Combined with Second-line Therapy for Patients with Advanced Liver Cancer — Replimune Inc.
- Study on the Safety and Effectiveness of Livmoniplimab and Budigalimab for Liver Cancer — AbbVie
- T-Cell Therapy (ECT204) for Adults with Advanced Liver Cancer (HCC) — Eureka Therapeutics Inc.
- Study on Targeting Ischemia-Induced Autophagy in Liver Cancer — VA Office of Research and Development
- Study on TheraSphere with Durvalumab and Tremelimumab for Liver Cancer (HCC) — Boston Scientific Corporation
- Study on Therasphere® and Systemic Therapy for High-Risk Liver Cancer — Northwestern University
- TheraSphere® for Treatment of Unresectable Hepatocellular Carcinoma — University of California, Irvine
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Hepatocellular Carcinoma to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.